Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
49
LXEO Quote, Financials, Valuation and Earnings
Last price:
$9.49
Seasonality move
:
-53.42%
Day range:
$9.11 - $9.45
52-week range:
$1.45 - $10.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.57x
Volume:
920.7K
Avg. volume:
1.3M
1-year change:
32.06%
Market cap:
$310.3M
Revenue:
--
EPS (TTM):
-$2.70
Analysts' Opinion
-
Consensus RatingLexeo Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $19.40, Lexeo Therapeutics, Inc. has an estimated upside of 107.49% from its current price of $9.35.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $9.35.
Fair Value
-
According to the consensus of 8 analysts, Lexeo Therapeutics, Inc. has 107.49% upside to fair value with a price target of $19.40 per share.
LXEO vs. S&P 500
-
Over the past 5 trading days, Lexeo Therapeutics, Inc. has underperformed the S&P 500 by -5.47% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Lexeo Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lexeo Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Lexeo Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Lexeo Therapeutics, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Lexeo Therapeutics, Inc. reported earnings per share of -$0.33.
Enterprise value:
196M
EV / Invested capital:
1.52x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.13x
EV / Free cash flow:
-1.83x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$2.1M
Return On Assets:
-68.21%
Net Income Margin (TTM):
--
Return On Equity:
-86.99%
Return On Invested Capital:
-80.69%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $37K | -- | -- | -- | -- | |
| Gross Profit | -$1.7M | -$2M | -$2.1M | -$509K | -$530K | |
| Operating Income | -$68.8M | -$93.4M | -$113.5M | -$31.5M | -$21.6M | |
| EBITDA | -$67.1M | -$91.4M | -$111.5M | -$31M | -$21.1M | |
| Diluted EPS | -$2.53 | -$2.84 | -$2.70 | -$0.89 | -$0.33 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $38.9M | $159.5M | $127.8M | |
| Total Assets | -- | -- | $54.7M | $173.9M | $143.8M | |
| Current Liabilities | -- | -- | $23M | $26.8M | $17.3M | |
| Total Liabilities | -- | -- | $32.5M | $34.5M | $23M | |
| Total Equity | -- | -- | $22.2M | $139.3M | $120.8M | |
| Total Debt | -- | -- | $10M | $8.3M | $6.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$66.8M | -$106.8M | -$17.8M | -$29.5M | |
| Cash From Investing | -- | -$567K | -$82.1M | -$83K | $35M | |
| Cash From Financing | -- | $188.9M | $72.9M | -$72K | $52K | |
| Free Cash Flow | -- | -$67.4M | -$107.2M | -$17.9M | -$29.8M | |
LXEO
Sector
Market Cap
$310.3M
$28.5M
Price % of 52-Week High
90.08%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-33.09%
-1.33%
1-Year Price Total Return
32.06%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$9.19
200-day SMA
Buy
Level
$5.07
Bollinger Bands (100)
Buy
Level
4.66 - 8.86
Chaikin Money Flow
Sell
Level
-6.1M
20-day SMA
Buy
Level
$9.12
Relative Strength Index (RSI14)
Buy
Level
53.81
ADX Line
Buy
Level
21.58
Williams %R
Neutral
Level
-41.989
50-day SMA
Buy
Level
$8.70
MACD (12, 26)
Buy
Level
0.13
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
25.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.1701)
Sell
CA Score
(Annual)
Level (-2.4063)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (5.5295)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, LXEO has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LXEO average analyst price target in the past 3 months is $19.40.
-
Where Will Lexeo Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lexeo Therapeutics, Inc. share price will rise to $19.40 per share over the next 12 months.
-
What Do Analysts Say About Lexeo Therapeutics, Inc.?
Analysts are divided on their view about Lexeo Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lexeo Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Lexeo Therapeutics, Inc.'s Price Target?
The price target for Lexeo Therapeutics, Inc. over the next 1-year time period is forecast to be $19.40 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LXEO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lexeo Therapeutics, Inc. is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LXEO?
You can purchase shares of Lexeo Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lexeo Therapeutics, Inc. shares.
-
What Is The Lexeo Therapeutics, Inc. Share Price Today?
Lexeo Therapeutics, Inc. was last trading at $9.49 per share. This represents the most recent stock quote for Lexeo Therapeutics, Inc.. Yesterday, Lexeo Therapeutics, Inc. closed at $9.35 per share.
-
How To Buy Lexeo Therapeutics, Inc. Stock Online?
In order to purchase Lexeo Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get LXEO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LXEO
Sector
P/E ratio
--
23.75x
PEG ratio
-0.13x
-0.01x
P/B ratio
2.57x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
LXEO
Sector
Revenue growth
--
4.85%
Earnings growth
62.71%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.46
-$0.20
Profitability
LXEO
Sector
Profitability FY 2024
-$2M
$3.6M
Return on invested capital
-80.69%
-30.98%
Return on assets
-68.21%
-27.62%
Return on equity
-86.99%
-36.69%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
23
Estimated Next Earnings Date
Feb
4
Balance Sheet
LXEO
Sector
Total cash
$122.8M
$27.2M
Short term investments
$86.5M
$25.7M
Total assets
$149.9M
$79.7M
Long term debt
$6.3M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is down 12.74% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 62.68% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 8.8% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
